moray

About Moray Wright

Moray is CEO of Parkwalk, which he co-founded in 2009.

15 January 2019

Parkwalk – 2018 in numbers

By |January 15th, 2019|

Flusso – Opportunities and UCEF V & VI investment

By |January 10th, 2019|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Funds V and VI, managed by Parkwalk, have participated in the first major financing round of Flusso, the University of Cambridge spin-out which has developed an innovative high-performance gas flow sensor.

Flusso is a 2018 spin-out from the High […]

YASA – The World’s Fastest Electric Powered Aeroplane

By |January 2nd, 2019|

This zero-emissions plane is expected to make a run for the record books with a target speed of 300+ MPH (480+ KMH).
Rolls-Royce is leading a highly specialised challenge to build the world’s fastest all-electric aircraft.

Inside a bustling hangar bay at the far end of Gloucestershire airport in South West England, a team of British […]

12 December 2018

Istesso – Parkwalk investment

By |December 12th, 2018|

Parkwalk are delighted to welcome Istesso to its portfolio following an investment from the Parkwalk Opportunities EIS Fund.

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a […]

Brainomix partners with Oxford University in UK Government funded £17.5 million AI Programme

By |December 7th, 2018|

Brainomix, an Oxford-based world leader in medical imaging software, is teaming up with the University of Oxford to become one of its technology providers for a £17.5m UK government funded project. Brainomix will demonstrate the significant health economic benefits of its AI-based proprietary imaging software solution, e-Stroke Suite, which is already used in routine clinical practice at […]

20 November 2018

Tom Hopkins joins Parkwalk

By |November 20th, 2018|

Parkwalk are delighted to announce that Tom Hopkins has joined the team as Business Development Director. Tom has worked alongside Parkwalk since early 2015 as one of the co-founders of Kin Capital who provide fundraising services to the Parkwalk EIS Fund and will continue to do so.

Tom has 13 years’ experience across the front, […]

Duel – University of Bristol Enterprise Fund II investment

By |November 5th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Duel.

Duel is a centralised hub for managing Ambassador programs and all elements for Customer Advocacy Marketing for brands. It works by taking customers, turning them into advocates, then empowering these advocates to tell a brand’s story and rigorously track the results. […]

Echion – UCEF V investment

By |November 1st, 2018|

We are delighted to announce that the University of Cambridge Enterprise Fund V has invested in a £1.5 million seed funding round (alongside an additional £600k Innovate UK grant) in to Echion Technologies, a spin-out from the University of Cambridge Engineering Department.

Echion is commercialising superfast charging lithium-ion battery cells for electric vehicles, and is seeking […]

12 October 2018

Oxbotica – appoints Fraser Robinson to drive global strategy

By |October 12th, 2018|

Oxbotica, the autonomous software company, today announces the appointment of Fraser Robinson to its board of directors. This follows Oxbotica’s recent completion of a £14 million investment which will support the next stage of its international development.

Robinson comes with a rare and proven track record, most recently leading Uber’s investment negotiations, strategy and partnerships […]

Vitamica – University of Bristol Enterprise Fund II investment

By |October 9th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Vitamica, a University of Bristol spin-out that aims to exploit a novel approach for determining the susceptibility of bacteria to antibiotics.

Resistance of bacteria to antibiotics is an increasing problem across the world, resulting in poorer healthcare […]

27 September 2018

Healthera – UCEF V investment

By |September 27th, 2018|

We are delighted to announce that the University of Cambridge Enterprise Fund V has invested in a £3m Series A financing round into Healthera, a provider of next-generation, pharmacy-integrated personal health management solutions.

Healthera connects patients to a platform of hundreds of pharmacies and NHS GPs, allowing them to order and track prescriptions, access clinical […]

Oxbotica – Parkwalk investment

By |September 19th, 2018|

Oxbotica, the autonomous vehicle software company, today announces the completion of a £14 million investment to support the next stage of its growth strategy. Funds have been secured from three leading investors: IP Group plc, Parkwalk Advisors and AXA XL (formerly XL Catlin).

The investment will be used to further accelerate Oxbotica’s sustained growth, which […]

AudioTelligence – University of Cambridge Enterprise Fund V investment

By |September 18th, 2018|

We have recently made an investment in a £3.1m seed funding round in to AudioTelligence for the University of Cambridge Enterprise Fund V.

AudioTelligence is delivering real-time audio processing technology for the enhancement of Automatic Speech Recognition (ASR) systems.

Speech control is being used increasingly in consumer electronics, with smart speakers being the world’s fastest-growing consumer […]

Lettus Grow – University of Bristol Enterprise Fund II investment

By |September 1st, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Lettus Grow.

Lettus Grow is a Bristol-based company supported by the award winning SETSquared incubator and the Oracle Global Cloud Accelerator. The company has developed a novel irrigation system to increase productivity in food production, with early […]

10 August 2018

Astellas announces acquisition of Quethera

By |August 10th, 2018|

Astellas Pharma Inc. and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.

Through this transaction, Astellas has acquired Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce […]

University of Cambridge Enterprise Fund VI launched

By |August 3rd, 2018|

Parkwalk are delighted to announce the launch of the University of Cambridge Enterprise Fund VI.

Launched in conjunction with Cambridge Enterprise, the University’s Technology Transfer and academic consulting subsidiary, the University of Cambridge Enterprise Funds offer alumni and investors the opportunity to invest in companies formed to develop and commercialise technology and intellectual property developed at the University of Cambridge in […]

Ilika – Parkwalk investment

By |August 1st, 2018|

We are delighted to announce that the Parkwalk Opportunities EIS Fund has participated in a £4.4m funding round in Ilika, an AIM listed company which specialises in materials innovation. The company has developed unique solid state battery technology which may have applications across the Internet of Things (IoT).

Ilika spun out of the University of […]

20 July 2018

Bramble Energy – Parkwalk investment

By |July 20th, 2018|

We have recently closed an investment in Bramble Energy , a UCL and Imperial College London spinout which has developed a unique, patent protected, printed circuit board (PCB) fuel cell – the PCBFC™.

The PCBFC™ utilises cost-effective production methods and materials from the PCB industry to reduce the cost and complexity of manufacturing of proton exchange […]

Undo – Parkwalk investment

By |July 13th, 2018|

We have recently closed an investment in Undo, a Cambridge company whose products transform the way organisations handle software quality issues. Undo helps improve customers’ software quality and productivity, enabling them to fix their ‘unfixable’ bugs, and offers huge improvements in development productivity.

Undo offers a new way of diagnosing and fixing Linux C/C++ application failures […]

23 June 2018

Microsaic Systems – Parkwalk closes follow on investment

By |June 23rd, 2018|

We are delighted to have participated in a placing for Microsaic Systems:
22 June 2018 Microsaic Systems plc (“Microsaic”, “Microsaic Systems” or the “Company”)
Result of General Meeting, Completion of Fundraising and Total Voting Rights
Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry (“MS”) instruments , is pleased to announce that, at its General Meeting held […]